<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/css" href="http://service.openkapow.com/rss20.css" ?>
<rss xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>RSS feed for http://press.novonordisk-us.com/internal.aspx?latestnews</title>
    <link>http://press.novonordisk-us.com/internal.aspx?latestnews</link>
    <description>News feed generated by RoboSuite.</description>
    <language>en</language>
    <lastBuildDate>Fri, 05 Dec 2008 18:00:08 GMT</lastBuildDate>
    <generator>RoboSuite 6.4</generator>
    <image>
      <title>RSS feed for http://press.novonordisk-us.com/internal.aspx?latestnews</title>
      <url>http://setup.openkapow.com/api/logo.gif</url>
      <link>http://press.novonordisk-us.com/internal.aspx?latestnews</link>
    </image>
    <item>
      <title>Study Finds Cost of Diabetes in the United States Exceeds $217 Billion</title>
      <link>http://press.novonordisk-us.com/internal.aspx?rid=442</link>
      <description>No description is available.</description>
    </item>
    <item>
      <title>Novo Nordisk Launches Levemir® Satisfaction Guarantee Program</title>
      <link>http://press.novonordisk-us.com/internal.aspx?rid=441</link>
      <description>No description is available.</description>
    </item>
    <item>
      <title>FDA Approves Additional Indication for Norditropin® for Small for Gestational Age (SGA) in Children</title>
      <link>http://press.novonordisk-us.com/internal.aspx?rid=440</link>
      <description>No description is available.</description>
    </item>
    <item>
      <title>Novo Nordisk increased operating profit by 15% in the first nine months of 2008</title>
      <link>http://press.novonordisk-us.com/internal.aspx?rid=439</link>
      <description>No description is available.</description>
    </item>
    <item>
      <title>Data from head-to-head phase 3 trial demonstrate that liraglutide is more effective than exenatide in treatment of type 2 diabetes</title>
      <link>http://press.novonordisk-us.com/internal.aspx?rid=437</link>
      <description>No description is available.</description>
    </item>
  </channel>
</rss>

